The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out ...

Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics ...

Yeezy isn’t the only company being called out for its “bait-and-switch” Super Bowl commercial, a Californian company called ...

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Telehealth company Hims & Hers is being called out over its Super Bowl ad going after Big Pharma and popular weight-loss ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.